

Development of an AI-Assisted Immune Cell-Targeted Anti-Inflammatory **** Lead Antibody for Atherosclerosis



CARDIOVASCULAR	Lead
Product Type	Antibody
Indication	Atherosclerosis
Target	****
MoA(Mechanism of Action)	**** antibody exerts anti-inflammatory effects by suppressing macrophage activation, reducing pro-inflammatory cytokine release, and inhibiting NF-κB-mediated inflammatory signaling.
Competitiveness	IMVASTECH is developing a first-in-class immune cell-targeted anti-inflammatory **** antibody therapeutic for atherosclerosis supported by strong translational evidence linking the target to disease severity in both preclinical and clinical settings. Leveraging AI-assisted antibody engineering and phage display technology, this precision immunomodulatory therapy is designed to selectively suppress pro-inflammatory cytokine release and NF-κB-driven inflammatory signaling, addressing residual inflammatory cardiovascular risk that persists despite current LDL-lowering standard-of-care therapies. Backed by a differentiated mechanism of action, strong human disease relevance, and strategic intellectual property positioning, the program represents a highly differentiated partnering opportunity in cardiovascular and cardiometabolic disease.
Development Stage	Lead
Route of Administration	Intravenous (IV), Subcutaneous (SC)

Any unauthorized distribution or reproduction of this material is strictly prohibited.